Evidence map›Paper›PMID 26065834›Full record

ArticleMolecules (Basel, Switzerland)2015

Computational Studies of Benzoxazinone Derivatives as Antiviral Agents against Herpes Virus Type 1 Protease.

Juliana F R Mello, Nathália C Botelho, Alessandra M T Souza, Riethe Oliveira, Monique A Brito, Bárbara de A Abrahim-Vieira, Ana Carolina R Sodero, Helena C Castro, Lucio M Cabral, Leonardo A Miceli and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Juliana F R MelloLaboratory of Molecular Modeling & QSAR Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro 21.944-970, RJ, Brazil. foncor@gmail.com.
Nathália C BotelhoLaboratory of Molecular Modeling & QSAR Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro 21.944-970, RJ, Brazil. nathbc1991@hotmail.com.
Alessandra M T SouzaLaboratory of Molecular Modeling & QSAR Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro 21.944-970, RJ, Brazil. amtsouza2@yahoo.com.br.
Riethe OliveiraLaboratory of Molecular Modeling & QSAR Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro 21.944-970, RJ, Brazil. ri_oliver@msn.com.
Monique A BritoLaboratory of Computational Medicinal Chemistry, Faculty of Pharmacy, Fluminense Federal University, Niterói 24.241-000, RJ, Brazil. moniquebrito@id.uff.br.
Bárbara de A Abrahim-VieiraLaboratory of Molecular Modeling & QSAR Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro 21.944-970, RJ, Brazil. babi_abrahim@hotmail.com.
Ana Carolina R SoderoLaboratory of Molecular Modeling & QSAR Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro 21.944-970, RJ, Brazil. acrsodero@gmail.com.
Helena C CastroLaboratory of Antibiotics, Biochemistry, Education and Molecular Modeling, Institute of Biology, Fluminense Federal University, Niterói 24.210-130, RJ, Brazil. hcastrorangel@yahoo.com.br.
Lucio M CabralLaboratory of Industrial Pharmaceutical Technology, Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro 21.944-970, RJ, Brazil. lmcabral2@ig.com.br.
Leonardo A MiceliLaboratory of Antibiotics, Biochemistry, Education and Molecular Modeling, Institute of Biology, Fluminense Federal University, Niterói 24.210-130, RJ, Brazil. leossj@hotmail.com.
Carlos R RodriguesLaboratory of Molecular Modeling & QSAR Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro 21.944-970, RJ, Brazil. rangelfarmacia@gmail.com.
Universidade Federal do Rio de Janeiro · BRUniversidade Federal Fluminense · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herpes simplex virus infections have been described in the medical literature for centuries, yet the the drugs available nowadays for therapy are largely ineffective and low oral bioavailability plays an important role on the inefficacy of the treatments. Additionally, the details of the inhibition of Herpes Virus type 1 are still not fully understood. Studies have shown that several viruses encode one or more proteases required for the production new infectious virions. This study presents an analysis of the interactions between HSV-1 protease and benzoxazinone derivatives through a combination of structure-activity relationships, comparative modeling and molecular docking studies. The structure activity relationship results showed an important contribution of hydrophobic and polarizable groups and limitations for bulky groups in specific positions. Two Herpes Virus type 1 protease models were constructed and compared to achieve the best model which was obtained by MODELLER. Molecular docking results pointed to an important interaction between the most potent benzoxazinone derivative and Ser129, consistent with previous mechanistic data. Moreover, we also observed hydrophobic interactions that may play an important role in the stabilization of inhibitors in the active site. Finally, we performed druglikeness and drugscore studies of the most potent derivatives and the drugs currently used against Herpes virus.

Indexed as

Models, MolecularAntiviral AgentsBenzoxazinesBinding SitesHerpesvirus 1, HumanHumansHydrogen BondingHydrophobic and Hydrophilic InteractionsMolecular ConformationMolecular Docking SimulationMolecular WeightPeptide HydrolasesProtease InhibitorsProtein BindingStructure-Activity RelationshipAntiviral AgentsBenzoxazinesPeptide HydrolasesProtease Inhibitorsbenzoxazinonescomparative modelingherpesvirusmolecular dockingprotease

Identifiers

PMID26065834
PMCPMC6272224
OpenAlexW1490899899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.